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The aim of Pharmaceutical Care programs is to improve patients’ quality of life, and such programs 
are particularly effective in the case of chronic diseases such as hypertension. The objective of this 
longitudinal study was to analyze a Pharmaceutical Care model for hypertensive patients receiving 
care within the Family Health Strategy (FHS). All patients were being seen by an FHS team affiliated 
to a primary healthcare unit in Goiânia, Goiás, Brazil. Fourteen patients participated in the study, 
with each patient receiving six home visits during the Pharmaceutical Care. Overall, 142 drug-related 
problems were reported, the most common concerning the ineffectiveness of treatment (33.8%). A total 
of 135 pharmaceutical interventions were performed, 92.6% of which involved pharmacist-patient 
communication, with 48.8% of these interventions being implemented. Cardiovascular risk decreased 
in three patients and remained unchanged in nine. In hypertensive patients with diabetes, fasting glucose 
levels were reduced in six out of nine cases. The Pharmaceutical Care model proposed here was effective 
in detecting drug-related problems and in proposing interventions to resolve or prevent these problems. 
Consequently, this may have contributed towards improving clinical parameters, such as fasting glucose 
levels and cardiovascular risk in hypertensive patients receiving care within the FHS.
Uniterms: Pharmaceutical care. Hypertension. Primary health care.
A Atenção Farmacêutica tem como objetivo conseguir resultados concretos que melhorem a qualidade 
de vida do paciente, contribuindo especialmente em doenças crônicas, como a Hipertensão Arterial. O 
objetivo deste estudo foi analisar um modelo de Atenção Farmacêutica a pacientes com Hipertensão 
Arterial assistidos pela Estratégia Saúde da Família (ESF). Trata-se de um estudo longitudinal realizado 
com pacientes assistidos pela ESF de uma Unidade Básica de Saúde de Goiânia-GO. Participaram do 
estudo, 14 pacientes que receberam seis visitas domiciliares para Atenção Farmacêutica. Registraram-
se 142 Problemas Relacionados a Medicamentos (PRM) sendo mais frequente a falta de efetividade 
do tratamento (33,8%). Realizaram-se 135 intervenções farmacêuticas, das quais 92,6% foram com a 
comunicação farmacêutico-paciente, em que 48,8% das intervenções foram implementadas. Observou-se 
redução do risco cardiovascular em três pacientes e nove pacientes não apresentaram alteração no nível 
de risco cardiovascular. Entre os pacientes hipertensos e diabéticos observou-se redução da glicemia 
de jejum em seis. O modelo de Atenção Farmacêutica proposto foi capaz de detectar PRM propondo 
intervenções para resolvê-los e preveni-los e, consequentemente, pode ter contribuído na melhora de 
parâmetros clínicos como glicemia de jejum e risco cardiovascular em pacientes hipertensos assistidos 
pela ESF. 
Unitermos: Atenção farmacêutica. Hipertensão arterial. Atenção primária à saúde.
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INTRODUCTION
The healthcare model proposed by the Brazilian 
National Health Service (SUS) promotes the universality 
of healthcare coverage and the integrality of healthcare, 
and endorses primary healthcare as a port of entry into the 
healthcare system (Cohn, 2008).
With integrality, Pharmaceutical Care becomes one 
of the components of the care process within the SUS, 
consisting of a set of actions aimed at providing access 
to and guaranteeing the rational use of drugs, with the 
practice of Pharmaceutical Care being inherent to these 
actions (Brasil, 2004).
Pharmaceutical Care is a professional practice 
in which the pharmacist assumes responsibility for the 
patient’s requirements regarding pharmacotherapy. It is 
consistent with the proposal of primary healthcare and may 
be defined as the responsible provision of pharmacotherapy 
for the purpose of achieving concrete results that improve 
the patient’s quality of life (Hepler, Strand, 1990). In 
fact, Pharmaceutical Care promotes adherence with the 
prescribed pharmacotherapy in a systematic, continuous 
and well-documented manner through the establishment 
of a pharmacist-patient relationship. The objective is to 
identify, resolve or prevent any drug-related problem 
that could interfere with the ultimate purpose of attaining 
satisfactory results through treatment (Cipolle et al., 
2006).
In primary healthcare, pharmaceutical interventions 
may effectively prevent drug-related hospitalizations 
(Royal et al., 2006). Nevertheless, in the primary 
healthcare network of the SUS, Pharmaceutical Care 
focuses on management and drug dispensing processes; 
hence the pharmacist is kept at a distance from the patient 
and from the healthcare team (Araújo et al., 2008; Foppa 
et al., 2008).
Ricieri et al. (2006) believe that current policies in 
Brazil regarding drugs and Pharmaceutical Assistance do 
not encourage the pharmacist to act within the scope of 
primary healthcare, particularly in the case of the Family 
Health Strategy (FHS) initiative where there is no standard 
reference for pharmaceutical services, with experiences 
in this area being incipient and poorly propagated. 
Nevertheless, some studies have reported positive results 
regarding the inclusion and professional contribution of 
pharmacists in family healthcare teams (Loch-Neckel, 
Crepaldi, 2009; Provin et al., 2010).
The intent of the FHS is to reorganize and redefine 
the current healthcare model based on a broadened concept 
of the health-disease process. The essence of the FHS 
initiative lies in the fact that it actively seeks to implement 
health interventions in the target population rather than 
waiting for demand, with a focus on implementing health-
related actions not only at an individual level but also 
within the individual’s family and the environment in 
which he/she lives. This is achieved principally through 
preventive actions, by integrating healthcare professionals 
into the community (Viana, Dal Poz, 2005).
The chronic diseases have a major impact on 
morbidity and mortality of patients and represent 
a challenge for healthcare services. Patients with 
chronic diseases such as hypertension may benefit from 
preventive strategies to detect and treat complications 
at an early stage, thus reducing morbidity and mortality 
and consequently, health-related costs (Ministério da 
Saúde, 2011). A recent study conducted in Goiás between 
2000 and 2008 showed that 17.2% of hospitalizations 
occurred as a result of cardiovascular conditions that 
could have been resolved at primary level (Batista et al., 
2012). Therefore, Pharmaceutical Care may represent an 
important tool within the FHS, benefitting patients with 
hypertension by controlling their blood pressure (Castro 
et al., 2006; Lyra Júnior et al., 2008; Morgado et al., 2011; 
Obreli-Neto et al., 2011, Aguiar et al., 2012b), improving 
adherence to antihypertensive drugs (Souza et al., 2007; 
Aguiar et al., 2012b) and optimizing metabolic control of 
carbohydrates and lipids (Kicklighter et al., 2006; Correr 
et al., 2011; Obreli-Neto et al., 2011).
There is a need for further studies to be carried out in 
this area, particularly within the FHS. The objective of the 
present study was to analyze a Pharmaceutical Care model 
for hypertensive patients within the FHS in a primary 
healthcare unit in Goiânia, Goiás, Brazil.
MATERIAL AND METHODS
The present study was approved by the Research 
Ethics Committee of the Federal University of Goiás, 
under protocol number 120/2007. This longitudinal study 
was conducted with hypertensive patients receiving care 
within the FHS at a primary healthcare unit in the northern 
health district of the municipality of Goiânia, Goiás, 
between September 2010 and February 2012.
This healthcare unit operates with four family 
healthcare teams with each team comprising a doctor, a 
nurse, a dentist, a nursing technician and six community 
health agents. It was selected because it is the only unit 
in the municipality that has developed a Pharmaceutical 
Care program.
The inclusion criteria for this study consisted 
of hypertensive patients living within the catchment 
area of the healthcare unit, who had been referred for 
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Pharmaceutical Care by the FHS teams and who had a 
history of difficult-to-control hypertension. In addition, 
the patients had to exhibit at least two of the following 
requisites adapted from those defined by Koecheler et 
al. (1989): blood pressure ≥ 140 x 90 mmHg; in use of 
at least three drugs; therapeutic regimen changed at least 
twice in the previous year; presence of comorbidities and 
a history of non-compliance either reported by the patient 
or observed by the investigators. A total of 22 patients 
who fulfilled these criteria were included; however, there 
were subsequently eight losses, due to loss of contact with 
four patients, two patients that did not complete the sixth 
visit and two patients who died. Thus, only 14 patients 
concluded the study.
Exclusion criteria consisted of patients under 30 or 
over 74 years of age and all subjects who did not fulfill the 
aforementioned inclusion criteria.
Six home visits lasting approximately one hour 
each were scheduled, with a mean interval of 30 days 
between visits. The visits were made by two pharmacists, 
who had been previously trained in data collection and 
Pharmaceutical Care in accordance with an adapted 
version of the Pharmacist’s Workup of Drug Therapy 
(PWDT) (Cipolle et al., 2006).
The PWDT method consists of clinical reasoning 
on the part of pharmacists caring for a patient through 
the establishment of a therapeutic pharmacist/patient 
relationship. According to this process, Pharmaceutical 
Care consists of three stages: 1) Analyzing the patient’s 
condition in relation to their pharmacotherapeutic needs; 
2) Planning the patient’s care or follow-up; and 3) 
Evaluating the results of follow-up (Cipolle et al., 2006).
The variables evaluated in the study included 
sociodemographic data, smoking habits, presence of 
diabetes mellitus, fasting glucose level, comorbidities, 
systolic and diastolic blood pressure, dyslipidemias, total 
cholesterol and fractions, cardiovascular risk, the number 
of drugs used, antihypertensives used, drug-related 
problems, adherence to antihypertensive pharmacotherapy 
and pharmaceutical interventions.
Questionnaires were applied to patients for the 
purpose of collecting sociodemographic data and 
information on smoking habits, the presence of diabetes 
mellitus and comorbidities. Patients who smoked were 
considered smokers irrespective of the number of 
cigarettes they smoked per day.
Blood pressure levels were determined at each 
home visit by indirect auscultation using a calibrated 
aneroid sphygmomanometer and a clinical stethoscope 
in accordance with the measurement procedures 
proposed in the VI Brazilian Guidelines on Hypertension 
(Sociedade Brasileira de Cardiologia, 2010). At each 
visit, two measurements were made, the first of which 
was disregarded.
The classification proposed by the IV Brazilian 
Guidelines on Dyslipidemias and the Prevention of 
Atherosclerosis (Sposito et al., 2007) was used to 
identify dyslipidemias, with total cholesterol, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglyceride levels being measured 
at the first and sixth visits, at which times fasting glucose 
was also determined.
Cardiovascular risk was evaluated in accordance 
with the Framingham risk score, which indicates the 
overall probability of cardiovascular disease for a 10-
year period. The Framingham risk score calculation 
was adapted and endorsed by the Brazilian Ministry of 
Health and takes age, gender, LDL and HDL cholesterol, 
smoking, diabetes mellitus and blood pressure into 
consideration (Ministério da Saúde, 2006).
Each patient’s medical prescriptions were evaluated 
to obtain information on the number of drugs and the 
classes of antihypertensives used.
Drug-related problems were identified by evaluating 
pharmacotherapy at each home visit. Problems were 
then classified in accordance with the definitions of 
Cipolle et al. (2006) into: 1) Indication (this refers to a 
need for additional medication or the use of unnecessary 
medication); 2) Effectiveness (this refers to the use of 
an inappropriately low dosage of a drug or use of an 
inappropriate drug); 3) Safety (this refers to the use of 
an inappropriately high dosage of a drug or to an adverse 
reaction to a drug); and 4) Adherence (this refers to non-
adherence to treatment).
Adherence to antihypertensive pharmacotherapy 
was determined by applying the questionnaire developed 
by Morisky, Green and Levine, and validated by Bloch et 
al. (2008): 1) Do you ever forget to take your medicine?; 
2) Are you careless at times about taking your medicine?; 
3) When you feel better do you sometimes stop taking 
your medicine?; 4) Sometimes if you feel worse when 
you take the medicine, do you stop taking it?. Individuals 
who answered “no” to all these questions were considered 
adherent.
Pharmaceutical interventions are part of the process 
involved in monitoring pharmacotherapy and consist of 
planned and documented acts carried out with the patient 
and the healthcare professional (Ivama et al., 2002) to 
prevent or resolve drug-related problems and to achieve 
the established therapeutic objectives (Cipolle et al., 
2006). Whenever necessary, these were carried out during 
the monitoring of pharmacotherapy and directed at the 
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patient and/or FHS team and classified in accordance with 
the objective of each intervention as pharmacological or 
non-pharmacological interventions. The pharmacological 
interventions were subdivided into those carried out for 
the purpose of optimizing treatment and those carried out 
for the purpose of prevention.
The type of communication used in the interventions 
was classified as pharmacist-patient or pharmacist-
physician. The outcome of each intervention was classified 
as: implemented (when there was agreement and the 
proposed management approach was carried out) or non-
implemented (when there was no agreement or when there 
was agreement but the proposed management approach 
was not carried out by the end of the study due to some 
difficulty).
The Statistical Software Package (SPSS®), version 
17.0, was used for data analysis. The Kolmogorov-
Smirnov test was used to verify the normality of the 
sample. Absolute and relative frequencies, means and 
standard deviations were calculated. Fisher’s exact 
test was used to evaluate the correlation between the 
interventions and the clinical results. Confidence level was 
defined as 95%, with p-values < 0.05 being considered 
statistically significant.
The categories defined in the calculation of the 
Framingham risk score were used to compare changes in 
systolic and diastolic blood pressure levels and in LDL 
cholesterol (Ministério da Saúde, 2006).
To compare changes in fasting glucose levels, 
the following classifications were used: ≤ 110 mg/dL, 
110-150 mg/dL, 151-270 mg/dL and > 270 mg/dL, as 
defined in the Brazilian Guidelines for the Treatment and 
Monitoring of Diabetes Mellitus (Sociedade Brasileira de 
Diabetes, 2007).
RESULTS
Fourteen patients, 12 women (85.7%) and 2 
men (14.3%), participated in the study. The mean age 
of these patients was 61.6 years. Table I shows the 
sociodemographic and clinical characteristics of the 
patients at baseline.
Overall, 142 drug-related problems were identified, a 
mean of 10.1 (standard deviation=5.6) per patient, with all 
patients experiencing at least three drug-related problems. 
Ineffectiveness of the treatment was the most common 
drug-related problem (33.8%), followed by problems with 
indication (24.6%), safety (23.2%) and adherence (18.3%). 
Non-adherence to pharmacotherapy was the least common 
of the drug-related problems; nevertheless, analysis of 
each individual patient showed that nine patients had 
TABLE I - Sociodemographic and baseline clinical characteristics 
of hypertensive patients receiving Pharmaceutical Care within 
the Family Health Strategy
Characteristic n (%)
Age group (years)
45 – 54 1 (7.1)
55 – 64 7 (50)
65 – 74 6 (42.9)
Educational level
Illiterate 2 (14.3)
Primary school 6 (42.9)
High school 5 (35.7)
University 1 (7.1)
Monthly family income
≤ 1 minimum salary 2 (14.3)
1-3 minimum salaries 8 (57.1)
> 3 minimum salaries 4 (28.6)
Risk factors 
Diabetes mellitus 9 (64.3)
Dyslipidemia 12 (85.7)
Smoking 1 (7.1)
Presence of at least 3 comorbidities 10 (71.4)
Number of drugs, mean (standard deviation) 7.6 (2.14)
Adherence to hypertension pharmacotherapy
Non-adherence 7 (50)
Adherence 7 (50)
this type of drug-related problem, with non-adherence to 
hypertensive medication involved in seven of these cases 
(Table I). At study endpoint, no change was found in 
patients’ adherence to antihypertensive pharmacotherapy.
A total of 135 pharmaceutical interventions were 
carried out. The most common interventions were 
performed with the intention of optimizing treatment 
(45.9%), particularly those involving pharmacist-patient 
communication (90.3%). Overall, 48.8% of interventions 
(n=66) were implemented, while 51.2% (n=69) were not. 
The interventions that proved most difficult to implement 
were the pharmacological interventions aimed at 
optimizing treatment as well as the non-pharmacological 
interventions (Table II).
Tab le  I I I  shows  the  p r inc ipa l  c l a s ses  o f 
antihypertensive drugs and the therapeutic regimens 
used to control hypertension in these patients. More than 
half the patients were found to be in use of a combination 
of three or more antihypertensive agents, with diuretics, 
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TABLE II - Description of the pharmaceutical interventions carried out during the study







Pharmacological intervention aimed at 
optimizing treatment 
62 (45.9%) 56 (90.3%) 6 (9.7%) 35 (56.5%) 27 (43.5%)
To recommend method of administration 15 15 0 6 9
To improve adherence with treatment 24 24 0 11 13
To initiate treatment 9 8 1 8 1
To review pharmacotherapy 13 8 5 9 4
To prevent drug interaction 1 1 0 1 0
Preventive pharmacological intervention 31 (23%) 29 (93.5%) 2 (6.5%) 8 (25.8%) 23 (74.2%)
To confirm medical prescription 2 1 1 0 2
To prevent adverse reactions 13 13 0 4 9
To recommend monitoring 10 10 0 2 8
To discontinue medication 3 2 1 1 2
To initiate treatment 3 3 0 1 2
Non pharmacological Intervention 42 (31.1%) 40 (95.2%) 2 (4.8%) 26 (62%) 16 (38%)
To provide counseling on lifestyle changes 31 31 0 16 15
To refer patient to another professional 8 6 2 8 0
To provide counseling on diabetic foot care 2 2 0 1 1
To provide counseling on the use of 
compression stockings
1 1 0 1 0
Total 135 (100%) 125 (92.6%) 10 (7.4%) 69 (51.2%) 66 (48.8%)
TABLE III - Use of antihypertensive drugs by hypertensive patients receiving care within the Family Health Strategy
Use of drugs 1st Visit n (%) 6th Visit n (%)
Therapeutic regimen
Monotherapy 2 (14.3) 2 (14.3)
Combination of two therapeutic classes 3 (21.4) 4 (28.6)
Combination of three or more therapeutic classes 9 (64.3) 8 (57.1)
Classes of antihypertensive drug
Diuretics 10 (71.4) 9 (64.3)
Angiotensin-converting enzyme inhibitors 9 (64.3) 8 (57.1)
Calcium channel blockers 8 (57.1) 8 (57.1)
Beta-blockers 7 (50) 7 (50)
Angiotensin II receptor blockers 4 (28.6) 4 (28.6)
Alpha-blockers 3 (21.4) 3 (21.4)
angiotensin-converting enzyme inhibitors and calcium 
channel blockers being the most common. As shown in 
Table II, 13 pharmaceutical interventions were performed 
in which there was a suggestion that pharmacotherapy 
should be reviewed; however, as shown in Table III, 
changes in therapeutic regimens were made in only two 
cases during follow-up.
Table IV compares the clinical parameters of 
these patients at the first and sixth visits. As shown, an 
improvement was found on at least one parameter in 
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12 cases. Cardiovascular risk level decreased in three 
patients, remained unaltered in nine and increased in one 
patient. In the remaining patient, cardiovascular risk could 
not be calculated due to missing data.
Fasting glucose, shown only for patients who had 
both hypertension and diabetes mellitus, was the parameter 
that proved most sensitive to change. Of the nine patients 
with hypertension and diabetes mellitus, glucose levels 
decreased in six cases (Table IV).
No correlation was found between the type of 
intervention implemented and systolic or diastolic blood 
pressure, cardiovascular risk, LDL cholesterol or fasting 
glucose levels (non-pharmacological interventions 
p=0.625; 0.500; 0.318; 0.571; 0.536; pharmacological 
interventions aimed at optimizing treatment p=0.625; 
0.500; 0.530; 0.536; 0.250; and those aimed at prevention 
p=0.357; 1.00; 0.530; 0.571; 0.750). Nevertheless, all 
six patients whose glucose levels improved had been 
submitted to at least one pharmacological intervention 
aimed at optimizing treatment.
DISCUSSION
The results of this study showed that drug-related 
problems were common in these hypertensive patients 
where this may be related to the considerable number of 
drugs that many participants were taking (polypharmacy). 
In this study, the mean number of drug-related problems 
per patient was higher than that reported in the studies 
conducted by Lyra Júnior et al. (2008) and Castro et 
al. (2006). The most common drug-related problem 
concerned the ineffectiveness of pharmacotherapy and 
this finding is in agreement with the studies conducted by 
Castro et al. (2006) and Provin et al. (2010).
As a consequence of the high number of drug-related 
problems, a substantial number of interventions were 
performed, most of which involved pharmacist-patient 
communication. These findings are consistent with the 
results of a study conducted by Romano-Lieber et al. (2002) 
in which 70% of the interventions were carried out with the 
patient, principally in the form of educational actions and 
counseling with respect to the therapeutic regimen.
Family members were often present during the 
pharmaceutical intervention, a fact that may have 
influenced patients’ conduct and decisions regarding 
the interventions. Studies have shown that in primary 
healthcare, the ability of the healthcare professional 
to communicate and intervene, with a focus that also 
includes the patient’s family, contributes towards the 
success of the actions (Wagner et al., 2004; Foppa et 
al., 2008).
In general, the rate of implementation of the 
interventions was poor. The interventions that proved the 
most difficult to implement were those pharmacological 
interventions aimed at optimizing treatment, either 
by proposing the initiation of treatment or reviewing 
pharmacotherapy, and also non-pharmacological 
interventions that referred the patient to another healthcare 
professional, thus making evaluation of the results 
impossible. This may have been due to the fact that these 
actions depended on being able to schedule medical 
consultations with specialists or other professionals and 
also on the availability of certain services within the public 
healthcare system.
Another factor that may have contributed to the 
inability to implement the interventions was the fact 
that few interventions were performed directly with 
the attending physician. This may have been due to a 
difficulty in communication between the investigating 
pharmacists and the physicians in the attending teams, 
rendering the discussion of cases difficult. This finding 
corroborates the results reported by Triller and Hamilton 
(2007) and Provin et al. (2010), who also conducted 
Pharmaceutical Care in home visits and believe that the 
lack of communication between pharmacist and prescriber 
leads to poor interventions being implemented.
The work of a multi-professional team is fundamental 
in ensuring integrated healthcare within the Family Health 
Strategy, since it permits different forms of dealing with 
the patient and their family within the intervention process, 
facilitating the exchange of information between the 
professionals in the team with the aim of optimizing results 
and establishing better interaction between the team and 
the community (Oliveira, Spiri, 2006).
TABLE IV - Changes in the clinical parameters of hypertensive patients receiving care within the Family Health Strategy









Improvement 3 (21.4%) 2 (14.3%) 3 (21.4%) 3 (21.4%) 6 (66.7%)
Unchanged 6 (42.9%) 10 (71.4%) 9 (64.3%) 6 (42.9%) 1 (11.1%)
Worsening 5 (35.7%) 2 (14.3%) 1 (7.1%) 4 (28.6%) 2 (22.2%)
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Adequate control of hypertension depends on 
behavioral changes such as adopting a healthy diet, 
practicing physical exercise regularly and cessation of 
smoking (Santos, Abreu-Lima, 2009). Nevertheless, 
interventions involving patient counseling, aimed at 
improving adherence and at implementing lifestyle 
changes, are the most difficult to put into effect, suggesting 
that achieving behavioral changes represents a challenge. 
According to Oliveira et al. (2009), changing life habits is 
a difficult task and leads to dissatisfaction in hypertensive 
patients, principally with respect to sustaining these new 
habits.
Such resistance may also have contributed to the 
absence of any significant changes in blood pressure 
control and, consequently, in patients’ cardiovascular 
risk level, although cardiovascular risk was found to 
decrease in some patients studied. Santschi et al. (2011) 
stressed the importance of interventions performed 
by pharmacists alone, or in conjunction with other 
professionals, in identifying and controlling the risk 
factors for cardiovascular disease.
Around half the interventions were performed to 
optimize pharmacological treatment in an integrated 
manner, not simply focusing on hypertension but also on 
the patient’s other health issues such as diabetes mellitus. 
This strategy is in line with the care provided within 
the Family Health Strategy, which has the integrality 
of care as one of its goals (Viana, Dal Poz, 2005). This 
may have collaborated towards the reduction in glucose 
levels experienced by the majority of patients with both 
hypertension and diabetes. Other studies have reported a 
significant reduction in glucose levels in diabetic patients 
receiving Pharmaceutical Care (Borges et al., 2010; Correr 
et al., 2011).
Diuretics and angiotensin-converting enzyme 
inhibitors were the most commonly prescribed classes 
of antihypertensives, a finding that mirrors the results 
reported by Vosgerau et al. (2011), who analyzed the use 
of antihypertensives in a family healthcare unit in the south 
of Brazil. This finding reinforces the fact that diuretics and 
angiotensin-converting enzyme inhibitors are the drugs 
of choice for the treatment of hypertension in view of the 
benefits conferred by the resultant reductions in blood 
pressure, cardiovascular events and mortality, as shown in 
the ALLHAT (2002) and HOPE (2000) studies.
The majority of the patients were found to be in 
concomitant use of at least three antihypertensive drugs, 
suggesting difficult-to-control hypertension, considering 
that the VI Brazilian Guidelines for Hypertension 
(Sociedade Brasileira de Cardiologia, 2010) recommend 
the combination of different classes of antihypertensive 
drugs when the patient is in the second or third stage 
of hypertension or in the first stage but with a high 
cardiovascular risk.
The majority of cases of non-adherence concerned 
antihypertensive pharmacotherapy. Around half the 
patients were adherent with therapy, a similar figure to 
that reported in the study conducted by Bloch et al. (2008). 
The poor educational level of the patients in the present 
study and the number of drugs used may have contributed 
towards this result, since other studies have reported 
poor adherence to be associated with educational level 
(Busnello et al., 2001; Araújo, Garcia, 2009), therapeutic 
regimen, and number of drugs prescribed (Leite, 
Vasconcelos, 2003). Furthermore, it may imply that further 
studies should be conducted to analyze the association 
between difficult-to-control hypertension, the time of 
treatment and patient adherence with pharmacotherapy, 
since these findings suggest the patient may become 
discouraged with the ineffectiveness of the therapy in 
controlling the disease.
Despite the 24 interventions aimed at optimizing 
adherence to treatment, adherence to antihypertensive 
pharmacotherapy remained unchanged at study endpoint. 
This finding contradicts the data reported by Chamorro 
et al. (2011), who also used the questionnaire developed 
by Morisky, Green and Levine but found an increase in 
adherence at the end of the study. Since sociocultural aspects 
as well as other factors are involved (Gusmão, Mion Jr., 
2006), improving compliance remains a difficult task.
Few studies have been conducted on Pharmaceutical 
Care within the Family Health Strategy initiative, making 
it difficult to compare the findings of the present study with 
others reported in the literature. The majority of previous 
studies on Pharmaceutical Care in hypertensive patients 
were conducted in outpatient clinics and community 
pharmacies (Castro et al., 2006; Lyra Jr et al., 2008; 
Morgado et al., 2011; Aguiar et al., 2012a).
The aim of the healthcare model proposed by the 
Family Health Strategy is not limited to curative actions 
but deals principally with the prevention of diseases 
and disorders and with promoting health. Therefore, its 
interventions occur even before the individual is aware 
of any health issue (Viana, Dal Poz, 2005). It is hence 
possible that lack of perception of a health problem may 
have altered the way in which the individuals in this study 
perceived and understood the recommended measures. 
In contrast, patients seeking medical care at outpatient 
clinics or community pharmacies do so because of an 
emerging health necessity perceived by the individual, 
thus facilitating their compliance with the proposed 
interventions.
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Another characteristic of this particular study is 
the fact that home visits were made by a professional 
pharmacist for the purpose of providing Pharmaceutical 
Care. Home visits are understood to represent a useful 
technique of interaction in family healthcare (Sakata et al., 
2007), since they provide a diversity of complementary 
information obtained by being able to observe the patient 
in their home environment and family relationships 
(Sakata et al., 2007; Albuquerque, Bosi, 2009). However, 
the present study has certain limitations. In some cases 
conversation between the pharmacist and the patient 
proved difficult, since the patient’s attention was diverted 
to domestic chores and family members, among other 
factors that can affect communication.
Furthermore, the frequency and regularity of 
these visits should be established with caution in order 
to prevent the patients from becoming discouraged or 
complacent. Mandú et al. (2008) saw it as a challenge to 
balance the benefits and values of home visits within the 
Family Health Strategy initiative against the dependency 
and complacency of users with respect to their health 
problems.
In conclusion, the results of the present study 
showed that Pharmaceutical Care is capable of detecting 
drug-related problems and of proposing interventions 
to resolve or prevent these problems. As a result, this 
may contribute towards improving clinical parameters 
such as fasting glucose levels and cardiovascular risk in 
hypertensive patients receiving care within the Family 
Health Strategy initiative.
Nevertheless, further studies, including an economic 
assessment, need to be conducted within the Family 
Health Strategy initiative to demonstrate the effectiveness 
of Pharmaceutical Care for controlling blood pressure 
and reducing cardiovascular risk. The results of such 
studies may provide support for actions to implement 
Pharmaceutical Care programs that would have a 
positive effect on healthcare and prevent complications 
in patients with chronic diseases, particularly those with 
hypertension.
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